Investor Relations

Press Releases

  • DATE
  • TITLE AND SUMMARY
  • VIEW
February 08, 2018

- Per agreement, milestone payments can exceed $100 million , in addition to double-digit million tiered royalties - TEL AVIV, Israel , Feb. 08, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announces that it has received a milestone payment from  NanoCarrier Co., Ltd....

January 03, 2018

Senior pharmaceutical executives with extensive experience in immuno-oncology, drug development, commercializing oncology medications and finance TEL AVIV, Israel , Jan. 03, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced the appointments of both David Hastings and Susan...

December 27, 2017

TEL AVIV, Israel , Dec. 27, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced the study initiation and first patient in its Phase 3 pivotal registration trial, OVAL, studying its lead candidate VB-111 (ofranergene obadenovec) in platinum-resistant ovarian cancer....

December 18, 2017

TEL AVIV, Israel , Dec. 18, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), announced new biomarker data supporting the direct link between lead asset VB-111’s dual mechanism of action and clinical effect on overall survival (OS) and progression-free survival (PFS) in patients from the...

November 21, 2017

TEL AVIV, Israel , Nov. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces it will provide a corporate overview via a Fireside Chat...

November 17, 2017

TEL AVIV, Israel , Nov. 17, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced the pricing of its previously announced underwritten...

November 16, 2017

TEL AVIV, Israel , Nov. 16, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it is offering to sell 2,500,000 ordinary shares in...

November 14, 2017

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , Nov. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced...

November 09, 2017

TEL AVIV, Israel , Nov. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Andrew Brenner , MD, will present a poster on VB-111...

November 07, 2017

TEL AVIV, Israel , Nov. 07, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast...

View all press releases »